DIFFERENCES IN TUBERCULAR AND CRYPTOCOCCAL MENINGITIS AS INITIAL MANIFESTATION OF AIDS

Mahim Mittal1, Sudheer Yadav2, Azhar Ali Khan3

1Professor and HOD, Department of Medicine, BRD Medical College, Gorakhpur, Uttar Pradesh, India.
2Lecturer, Department of Medicine, BRD Medical College, Gorakhpur, Uttar Pradesh, India
3Associate Professor, Department of Medicine, BRD Medical College, Gorakhpur, Uttar Pradesh, India.

ABSTRACT

BACKGROUND

Tuberculous meningitis (TBM) and cryptococcal meningitis (CCM) are among the most common CNS opportunistic infections in patients with HIV/AIDS and have a high mortality. They can be the initial manifestation of HIV infection. CCM and TBM present with a near similar clinical picture. Differentiation between these two is difficult on clinical ground. Also, basic cerebrospinal fluid (CSF) characteristics are frequently indistinguishable.

The present study was designed to observe the differences in clinical presentation and outcomes between CCM and TBM in newly diagnosed HIV patients.

MATERIALS AND METHODS

This study was a descriptive study. Patients presenting with chronic meningitis, who tested positive for HIV were included in the study. Their detailed history, physical examination, CD4 count, cerebrospinal fluid examination including India Ink preparation and Cryptococcal antigen test (CRAg) were done. CRAg was done in CSF by Cryptococcal Antigen Latex Agglutination System. Patients were treated as per standard protocols and outcome was assessed at four months. The collected data was analysed by descriptive statistical methods.

RESULTS

A total of 94 patients were studied. Out of all 45.74% cases were of TBM, 36.17% of CCM and 18.0% of other OI. Male to female ratio in CCM was 6:1 and in TBM was 5.7:1. Mean age and CD4 count of CCM patients were 37 ± 10.74, 81 ± 28.42 and of TBM were 38 ± 7.80, 84 ± 47.1. Headache was more prevalent in CCM patients (98%) than TBM (79%). CSF was near normal in CCM patients. In comparison to TBM (43.3%), mortality was higher in CCM group (56.0%) at four months followup. Low CD4 count was associated with poor prognosis.

CONCLUSION

Meningoencephalitis is not an uncommon initial presentation in HIV/AIDS patients. TBM and CCM are the most common causes. Both have common clinical presentation, but CSF findings in CCM patients are near normal in comparison to TBM. Prognosis of both the diseases is poor in spite of full treatment, but worst in CCM.

KEYWORDS

Cerebrospinal Fluid, Cryptococcal Meningitis, Opportunistic Infection, Tubercular Meningitis.


BACKGROUND

The HIV epidemic has dramatically affected the spectrum of central nervous system disease. In HIV patients both TBM and CCM are the commonest cause of nonpyogenic meningitis. CCM and TBM present with a similar clinical picture of chronic meningitis.[1] Differentiation between these two is difficult on clinical ground. Also, basic cerebrospinal fluid (CSF) characteristics are frequently indistinguishable as both organisms classically produce a lymphocytic pleocytosis with high CSF protein levels.[2] In resource poor settings, laboratory tools are limited and confirmatory microbiological diagnosis is often not possible.

The global annual burden of cryptococcal meningitis (CCM) is estimated at 957,900 cases resulting in an estimated 624,700 deaths within 3 months of cryptococcal infection.[3] Even with antiretroviral therapy (ART) availability, CM-related mortality remains high.[4] Most CCM occurs in AIDS patients with advanced immunosuppression. Early diagnosis and treatment is paramount to reducing CCM-related mortality. CCM is subacute meningitis, in which the polysaccharide CRAg is detectable in serum a median of 3 weeks prior to onset of clinical symptoms.[5] The sub-acute nature may allow for effective interventions.

Tuberculous meningitis (TBM) accounts for a substantial proportion of cases, particularly in high tuberculosis (TB) prevalence areas. Evidence shows that HIV-infected individuals are at greater risk of developing TBM, particularly at more advanced stages of immune depression[6] with mortality rates as high as 67%.[7,8,9] Despite treatment, mortality and long-term disability still remains unacceptably high. Thereby iterating that prevention, early recognition, diagnosis and appropriate treatment are fundamentals of improving outcome.[10]
MATERIALS AND METHODS

Study Design

This descriptive study was conducted over a period of one academic year from September 2014 to August 2015 in the Department of Medicine, BRD Medical College and associated Nehru Chikitsalaya, Gorakhpur. Patients presenting with feature suggestive of meningoencephalitis and also tested positive for HIV were included in the study. Demographic characteristics, history of illness, clinical finding, routine investigations and CSF analysis was done for proteins, sugar, cell count, cell type, India Ink smear and cryptococcal antigen. Patient was classified as CCM on detection of the Cryptococcal antigen by CALAS or Cryptococcus demonstrated by India Ink preparation. Diagnosis of TBM was based on CSF pleocytosis and lymphocytic predominance. All CCM patients were put on amphotericin B (0.7 mg/kg body weight) for 2 weeks and oral fluconazole 200 mg twice daily for 8 weeks followed by 200 mg daily. In TBM patients, ATT started as per standard protocols. In both groups, anti-retroviral therapy was started after 2 weeks. Followup of the cases was done at 4 months. Cryptococcal antigen was demonstrated by latex agglutination test (Latex Crypto Antigen Detection System, Bharat Biologics Sciences). Patients with age less than 15 years with other opportunistic infections without CNS involvement and patients who had diabetes or any other chronic illness like chronic liver diseases, kidney diseases or other endocrinial diseases were excluded from the study.

Statistical Methods

The collected data was analysed by descriptive statistical methods. At no stage, identity of individual was disclosed. Continuous data were reported using the following descriptive statistics: number of observations (n), mean, standard deviation, minimum and maximum value. For analysing continuous data, student’s t-test was carried out. Categorical data were presented using frequency (n) with percentage (%) and comparison was done using Chi-square test. All P values for efficacy analyses were calculated at 0.05 level of significance. All statistical analyses were performed using GraphPad Prism software, Version 7.0.

RESULTS

The HIV seropositive individuals (94 cases) included in this study had the age ranging from 15 - 65 years with maximum age of presentation between 3rd and 4th decade (>76%). Male constitute (85.45%) of the patients are as shown in Table 1. Male to Female ratio in CCM group was ≈6:1 and in TBM 5.7:1. Mean age and CD4 count in CCM patients were (37 ± 10.74, 81 ± 28.42) and in TBM were (38 ± 7.80, 84 ± 47.1).

There were 18.10% of patients with CD4 count < 50, 53.19% with CD4 count 51 - 100, 24.46% with CD4 count 101 - 200 and 4.25% with CD4 count > 200, Fig. 1. Tubercular meningitis was the most common diagnosis seen in 45.74% cases followed by cryptococcal meningitis accounts for 36.17% cases and others 18.09%.

The clinical presentation of patients included fever, headache, vomiting, altered sensorium, neck stiffness, seizure and cranial nerve palsy. Headache was the common presenting symptoms in Cryptococcal meningitis (98%). Headache was severe in intensity and situated bifrontally in CCM, whereas in TBM it was generalised. Fever was next presenting symptom in both groups. Fever was longstanding and dull in nature. Although cranial nerve involved in less number in both groups, but sixth cranial nerve was most commonly involved followed by seventh and third cranial nerve involvement, Table 2.

CSF analysis in TBM group of patients shows mean protein content and mean cell count were very high (236.78 ± 48.86, 23 ± 17.42) in comparison to cryptococcal meningitis (52.52 ± 19.65, 26.03 ± 20.70) group of patients. CCM group of patients had near normal CSF.

Patients were treated as per standard protocols and outcome was assessed at fourth month. During hospital course 11 (30.5%) CCM patients and 13 (30.2%) TBM patients refused full treatment and left against medical advice and remaining 25 (69.44%) CCM patients and 30 (69.77%) TBM patients were discharged at 3 weeks. At the time of discharge patients in both groups regained full consciousness, well oriented to time, place and person. After 4 months, out of 25 CCM patients 14 (56.0%) patients and out of 30 TBM patients 13 (43.3%) patients expired at followup. CCM patients who died, 9 patients died within 4 weeks of discharge and 5 patients died within 12 weeks, whereas in TBM patients died within 10 weeks. The result was significant on comparison of CD4 count with outcome of discharged patients (survivor vs. non-survivor) in CCM, but not in TBM patient. The cause of death could not be ascertained in both groups, as they were out of hospital deaths (Table 3).

<table>
<thead>
<tr>
<th>Age (Yrs.)</th>
<th>Male</th>
<th>Female</th>
<th>Total (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>15-20</td>
<td>3</td>
<td>5</td>
<td>8 (8.5)</td>
</tr>
<tr>
<td>21-30</td>
<td>32</td>
<td>5</td>
<td>37 (39.36)</td>
</tr>
<tr>
<td>31-40</td>
<td>32</td>
<td>3</td>
<td>35 (37.23)</td>
</tr>
<tr>
<td>41-50</td>
<td>11</td>
<td>1</td>
<td>12 (12.7)</td>
</tr>
<tr>
<td>51-65</td>
<td>2</td>
<td>0</td>
<td>2 (2.12)</td>
</tr>
<tr>
<td>Total</td>
<td>80</td>
<td>14</td>
<td>94</td>
</tr>
</tbody>
</table>

Table 1. Demography - Age and Sex Distribution

<table>
<thead>
<tr>
<th>Study Characteristic</th>
<th>CCM N=36</th>
<th>TBM N=43</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age in year</td>
<td>37 ± 10.74</td>
<td>38 ± 7.80</td>
<td>NS†</td>
</tr>
<tr>
<td>Male: female</td>
<td>6:1</td>
<td>5:7.1</td>
<td>NS†</td>
</tr>
<tr>
<td>Headache</td>
<td>35 (97.22%)</td>
<td>34 (79.06%)</td>
<td>NS†</td>
</tr>
<tr>
<td>Vomiting</td>
<td>21 (58.33%)</td>
<td>33 (76.74%)</td>
<td>NS†</td>
</tr>
<tr>
<td>Fever</td>
<td>26 (72.2%)</td>
<td>34 (79.06%)</td>
<td>NS†</td>
</tr>
<tr>
<td>Altered sensorium</td>
<td>13 (36.11%)</td>
<td>29 (67.44%)</td>
<td>NS†</td>
</tr>
<tr>
<td>Neck stiffness</td>
<td>12 (33.3%)</td>
<td>26 (60.46%)</td>
<td>NS†</td>
</tr>
<tr>
<td>Seizure</td>
<td>4 (11.1%)</td>
<td>6 (13.95%)</td>
<td>NS†</td>
</tr>
<tr>
<td>GN Palsy</td>
<td>5 (13.9%)</td>
<td>9 (20.9%)</td>
<td>NS†</td>
</tr>
<tr>
<td>CSF India ink</td>
<td>32 (91.66%)</td>
<td>0</td>
<td>S*†</td>
</tr>
<tr>
<td>Glucose</td>
<td>56.29 ± 13.94</td>
<td>46.07 ± 25.91</td>
<td>S (0.0317)†</td>
</tr>
<tr>
<td>Protein</td>
<td>52.52 ± 19.65</td>
<td>236.78 ± 48.87</td>
<td>S (0.001)†</td>
</tr>
<tr>
<td>Cell Count</td>
<td>26.03 ± 20.70</td>
<td>140.23 ± 17.42</td>
<td>S (0.001)†</td>
</tr>
<tr>
<td>Lymphocytes</td>
<td>83.78 ± 18.13</td>
<td>75.37 ± 22.86</td>
<td>NS (0.780)†</td>
</tr>
<tr>
<td>Polymorphs</td>
<td>16.22 ± 18.13</td>
<td>24.86 ± 22.99</td>
<td>NS (0.174)†</td>
</tr>
<tr>
<td>Mortality at 4 months</td>
<td>14 (56.0%)</td>
<td>13 (43.3%)</td>
<td>NS†</td>
</tr>
</tbody>
</table>

Table 2. Comparison of Study Characteristics between CCM and TBM Patients

†Student t-test
* Chi-square test
**DISCUSSION**

Meningoencephalitis is not an uncommon initial presentation in HIV/AIDS. Most patients in this study presented in very late stage and their CD4 count were < 100 cells/µL. Mean CD4 count in CCM patients is 81 ± 28.42 and in TBM is 84 ± 47.1. They were very prone to opportunistic infection. Similar finding in study of Zoseph R Zunt shows that infection of the CNS may occur during any stage of HIV infection, but opportunistic infection occurs only during late-stage infection when the CD4 count fall < 200 cells/µL.[11]

Aleksandra Leligowicz et al study found tubercular meningitis (TBM) to be the most common diagnosis (25.4%) followed by acute bacterial meningitis (22.5%), viral meningitis (14.1%) and cryptococcal meningitis (13%).[12] In another study Hakim et al, Zimbabwe, cryptococcal meningitis was the most common diagnosis (45%) followed by mononuclear meningitis (27%), acute bacterial meningitis (16%) and TBM (12%). In our study, tubercular meningitis was the most common diagnosis (45.74%) cases followed by cryptococcal meningitis (36.17%) cases and others (18.05%) cases.

Headache was the common presenting symptoms in Cryptococcal meningitis (~98%), whereas in TBM group most patients presented with other symptoms as well like headache (79.06%), fever (79%), neck stiffness (60.46%) and altered sensorium (67.44%). A study from Uganda, Jacinta Oyella et al and Hakim, James G et al from Harare shows similar clinical feature.[13,14] Although, altered sensorium and neck rigidity was seen in less number of cases of CCM, the difference was not significant.

CSF shows significant high protein (236.78 ± 48.86 vs. 52.52 ± 19.65), cell counts (140.23 ± 17.42 vs. 26.03 ± 20.70) and low sugar levels (46.071 ± 25.91 vs. 56.29 ± 13.94) in patients of TBM vs. CCM. These features use information which would be available in healthcare facilities with even the most basic of resources. CCM is associated with the presence of headache and low CSF white blood cell count, while TBM is associated with the presence of headache, fever, neck stiffness, high protein and cell count.

Mortality in both groups was high and significant number of patients did not continue treatment even though the medications were provided to them by hospital. The large number of defaulters make statistical interpretation difficult, but the only feature we could relate to mortality was low CD4 count in patients of CCM.

**CONCLUSION**

Meningoencephalitis due to the CCM or TBM is not an uncommon initial presentation in HIV/AIDS patients. Although clinical manifestations of both are nearly same, high protein and cells count favours diagnosis of TBM. Prognosis of CCM is worse than that of TBM and is related to low CD4 count. Presentation with CNS opportunistic lead to poor outcome in spite of full treatment.

**ACKNOWLEDGEMENT**

I extend my gratitude to all the technical and laboratory staffs of ART centre, BRD Medical College, Gorakhpur, for their cooperation and encouragement to carry out this study.

**REFERENCES**


